Loncastuximab Tesirine
21-622
Phase 2 small_molecule active
Quick answer
Loncastuximab Tesirine for Waldenstrom Macroglobulinemia is a Phase 2 program (small_molecule) at ADC Therapeutics SA with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ADC Therapeutics SA
- Indication
- Waldenstrom Macroglobulinemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active